BAKER BROS. ADVISORS LPBAKER BROS. ADVISORS LP

Institutional investor · Portfolio as of Q1 2026

Top Holdings84 positions

Checking export access…
Activity:
INCY

INCYTE CORP

30.7M$2.9B16.6%$84.99+10.75%
29 qtrssince 2019-Q1
Increased
62
ONC
ONC
ADR

BEONE MEDICINES LTD

8.8M$2.6B15.0%$149.70+98.38%
29 qtrssince 2019-Q1
Unchanged
0
INSM

INSMED INC

7.4M$1.2B7.0%$85.98+90.19%
29 qtrssince 2019-Q1
Increased
70
MDGL

MADRIGAL PHARMACEUTICALS INC

2.1M$1.1B6.4%$167.08+213.30%
29 qtrssince 2019-Q1
Unchanged
0
ACAD

ACADIA PHARMACEUTICALS INC

42.9M$954.9M5.5%$27.48-19.01%
29 qtrssince 2019-Q1
Unchanged
0
RVMD

REVOLUTION MEDICINES INC

9.6M$929.3M5.3%$30.86+215.15%
21 qtrssince 2021-Q1
Increased
62
CELC

CELCUITY INC

7.9M$903.5M5.2%$24.80+360.18%
11 qtrssince 2023-Q3
Unchanged
0
KOD

KODIAK SCIENCES INC

19.9M$759.3M4.4%$33.21+14.79%
29 qtrssince 2019-Q1
Unchanged
0
KYMR

KYMERA THERAPEUTICS INC

8.7M$721.1M4.1%$40.89+103.67%
23 qtrssince 2020-Q3
Unchanged
0
SMMT

SUMMIT THERAPEUTICS INC

36.4M$690M4.0%$12.42+52.65%
8 qtrssince 2024-Q2
Unchanged
0
PRAX

PRAXIS PRECISION MEDICINES I

1.8M$564.9M3.2%$208.46+54.56%
9 qtrssince 2024-Q1
Increased
82
RYTM

RHYTHM PHARMACEUTICALS INC

5.6M$487.4M2.8%$24.17+259.89%
29 qtrssince 2019-Q1
Unchanged
0
ALKS

ALKERMES PLC

10M$354M2.0%$26.97+31.10%
8 qtrssince 2024-Q2
Unchanged
0
GRAL

GRAIL INC

4M$208.2M1.2%$41.82+23.57%
6 qtrssince 2024-Q4
Increased
76
EWTX

EDGEWISE THERAPEUTICS INC

6.6M$207.1M1.2%$15.77+99.73%
21 qtrssince 2021-Q1
Unchanged
0
IONS

IONIS PHARMACEUTICALS INC

2M$153.8M0.9%$74.82+0.36%
3 qtrssince 2025-Q3
Increased
49
KNSA

KINIKSA PHARMACEUTICALS INTL

2.8M$136.1M0.8%$18.70+157.45%
8 qtrssince 2024-Q2
Unchanged
0
IMVT

IMMUNOVANT INC

5.5M$135.6M0.8%$21.09+17.80%
11 qtrssince 2023-Q3
Unchanged
0
ROIV

ROIVANT SCIENCES LTD

4.9M$134.8M0.8%$13.76+101.29%
14 qtrssince 2022-Q4
Decreased
0
IDYA

IDEAYA BIOSCIENCES INC

3.9M$131.5M0.8%$23.89+39.46%
15 qtrssince 2022-Q3
Increased
46
$17.4B
AUM
84
Positions
Q1 2026
Filing
HI rating · 3.5/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2024-Q4$9,361,492,374-2.97722464425%
2025-Q1$9,036,702,464-3.46942450012%
2025-Q2$10,307,840,45914.0663920281%
2025-Q3$13,838,782,04734.2549111237%
2025-Q4$17,078,624,10523.4113236772%
2026-Q1$17,415,689,9291.97361228825%
Activity profile
$ moved · Q1'26
New10%Increased66%Decreased11%Exited14%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 3.3 years
<1Q6%1-4Q14%1-2Y17%2Y+63%

BAKER BROS. ADVISORS LP manages $17.4B across 84 positions as of Q1 2026. Top holdings: INCY (16.6%), ONC (15.0%), INSM (7.0%). Fund DNA: Concentrated Value. HoldingsIntel Score: 3.5/5.0.

Q1 2026 Summary

Added MIRM, EVMN, AKTS and 4 more; exited RARE, TERN, BCRX and 6 more; increased 18, led by PRAX (+626,710 shares); trimmed 6, led by IMCR (−1.6M shares). Top move: PRAX (INCREASED, conviction 82). Portfolio: $17.4B across 84 positions.

Top holdings by portfolio weight

Total AUM$17B
INCY16.62%
ONC15.00%
INSM6.97%
MDGL6.44%
ACAD5.48%
RVMD5.34%
CELC5.19%
KOD4.36%
KYMR4.14%
SMMT3.96%
Other3.24%

Portfolio allocation by GICS sector

Sectors1
Healthcare100.00%

Behavioral investing profile

Checking access…
Concentrated Value- primarily Healthcare
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Strong(3.5 / 5.0)
Holdings P&L49
Conviction57
Concentration100
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
7Q
INCYINCYINCYTE CORP
Q4 2024 → Q2 2026+23,310 shares+$1.5B
5Q
IDYAIDYAIDEAYA BIOSCIENCES INC
Q2 2025 → Q2 2026+3.9M shares+$169.3M
3Q
DSGNDSGNDESIGN THERAPEUTICS INC
Q4 2025 → Q2 2026+965,548 shares+$25.9M
Checking access…

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used